An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
VERDICT
The label
Markdown
read at $8.96
Vir Biotechnology, Inc. holds its Markdown at $8.96.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-12
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 45 days
Price
$8.96
Valuation
N/A trailing · -3.59 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.59
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$8.96
N/A P/E · -3.59 fwd
Our fair value
$17.92
100% discount
Analyst target (avg)
$20.00
+123% to current
Target low $15.00Analyst target rangeTarget high $30.00
▲ current $8.96 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$8.96
you are here
Conservative
$15.00
+67%
Analyst avg
$20.00
+123%
Our fair value
$17.92
+100%
Analyst high
$30.00
+235%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
19,582.50%
Profit margin
-83.00%
Debt to equity
9.49
Analyst consensus
Strong Buy · 9 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its revenue purity. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 9.8% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 31.4% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 23.2% of assets, under the 49% limit.Pass
Revenue purity60.5% of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Clinical stage bets rarely deliver on paper promise
A company whose entire value sits in unproven drugs for infectious diseases is like funding a race car that has never left the workshop. Vir Biotechnology trades at half our calculated fair value with a forward multiple that reflects deep losses, yet the opportunity rating stays at none because clinical pipelines this early carry failure rates that wipe out capital fast.
The business shows zero profit margins and a negative return on equity of 48 percent, which is normal for a firm still burning cash on trials. Even with an ethical screen that passes cleanly and analyst targets clustered around 21 dollars, the absence of any moat or commercial product leaves the upside looking more like a lottery ticket than a repeatable business.
Risk sits in the binary outcomes of late stage data and dilution that often follows missed milestones. Currency or market swings matter less here than the simple fact that most such pipelines never reach paying customers. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in VIR's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
VIR trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21. Entered 2026-08-16 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-08-16Markdown$8.96+4.1%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18Markdown$8.61+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 52%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (9 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03Markdown$8.61+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$8.61Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
POLITICAL
The political ledger · congressional disclosures
Disclosures naming VIR
Date
Politician
Party
Type
Amount
7 Jul2026
Mark Warner
Democrat
buy
50K–100K
30 Jun2026
Gil Cisneros
Democrat
buy
1K–15K
2 Jul2026
Mark Warner
Democrat
buy
50K–100K
2 Jul2026
Mark Warner
Democrat
buy
100K–250K
18 Jun2026
Don Beyer
Democrat
buy
50K–100K
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$9.29
-11.2%
·
$888
-11.2%
2 months
$9.50
-13.2%
·
$868
-13.2%
3 months
$9.48
-13.0%
·
$870
-13.0%
6 months
$6.63
+24.4%
·
$1,244
+24.4%
1 year
$5.42
+52.2%
·
$1,522
+52.2%
2 years
$11.21
-26.4%
·
$736
-26.4%
3 years
$25.43
-67.6%
·
$324
-67.6%
5 years
$45.53
-81.9%
·
$181
-81.9%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever VIR does next, these words stay.
Vir Biotechnology, Inc. · VIR · Markdown · $8.96
Recorded 2026-08-12 · before the outcome · scored mechanically
